SDMA-d6

• UNSPSC Description:

  SDMA-d6 is the deuterium labeled SDMA. SDMA (Symmetric dimethylarginine) is an endogenous inhibitor of nitric oxide (NO) synthase activity[1][2].

• Target Antigen:

  Endogenous Metabolite

• Type:

  Isotope-Labeled Compounds

• Related Pathways:

  Metabolic Enzyme/Protease

• Field of Research:

  Inflammation/Immunology

• Purity:

  98.07

• Solubility:

  H2O : 50 mg/mL (ultrasonic)

• Smiles:

  OC([C@@H](N)CCC/N=C(NC([2H])([2H])[2H])/NC([2H])([2H])[2H])=O

• Molecular Weight:

  208.29

• References & Citations:

  [1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216. |[2]Bode-Böger SM,et al. Symmetrical dimethylarginine: a new combined parameter for renal function and extent ofcoronary artery disease.|[3]Schepers E, et al. Symmetric dimethylarginine as a proinflammatory agent in chronic kidney disease.Clin J Am Soc Nephrol. 2011 Oct;6(10):2374-83.|[4]Nabity MB, et al. Symmetric Dimethylarginine Assay Validation, Stability, and Evaluation as a Marker for the EarlyDetection of Chronic Kidney Disease in Dogs. J Vet Intern Med. 2015 Jul-Aug;29(4):1036-44.|[5]Veldink H, et al. Effects of chronic SDMA infusion on glomerular filtration rate, blood pressure, myocardial function and renal histology in C57BL6/J mice. Nephrol Dial Transplant. 2013 Jun;28(6):1434-9.

• Shipping Conditions:

  Blue Ice

• Storage Conditions:

  -20°C (Powder, stored under nitrogen)

• Clinical Information:

  No Development Reported

• CAS Number:

  1331888-08-4